MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable
Brief description of study
The purpose of this research study is to: • Test the safety of the study drug, pembrolizumab (MK-3475) • Test how your cancer responds to one of the following: o Pembrolizumab plus radiation therapy (RT) with or without cisplatin after surgery o RT with or without cisplatin after surgery.
Clinical Study Identifier: s18-00142
ClinicalTrials.gov Identifier: NCT03765918
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
